Heidelberg Pharma GmbH?provides pre-clinical drug discovery and development services, including explorative pharmacology in the field of cancer, autoimmunity and inflammation, hand-in-hand with bioanalytical methods. The company’s services are characterized by a high degree of flexibility, rapid turn-around and consistent high quality.
Heidelberg Pharma’s own R&D flagship is its proprietary 2nd?generation ADC technology for more effective anti-cancer drugs. The company has?developed a new ADC technology based on the most potent RNA-polymerase II inhibitor amanitin, a bicyclic octapeptide isolated from the Green Deathcap mushroom?Amanita phalloides.
Amanitin interferes with the eukaryotic transcription process at very low intracellular concentrations, making it an ideal drug for the use with antibodies binding at low-copy number antigens.
Heidelberg Pharma and its cooperation partners have shown outstanding activity of amanitin-based ADCs in therapy-resistant tumor cells, e.g. cells expressing multi-drug resistant transporters, tumor-initiating cells and non-dividing cells at picomolar concentrations. The tolerability and therapeutic window of amanitin-ADCs has been determined in different rodent and non-human primate models. Furthermore, amanitin has a water-soluble structure, resulting in ADCs with low tendency for aggregation, even using higher DAR (Drug to Antibody) ratios.
Schriesheimer Str. 101
68526 Ladenburg
Germany
Web:?Heidelberg Pharma
